Bristol-Myers Company

Bristol-Myers Squibb Compnay

Schering Corporation

Bristol Meyers Squibb Company

James A Matson

Kin S Lam

Jacqueline M Mattei

James A Bush

Salvatore Forenza

Koji Tomita

Murray A Kaplan

Terrence W Doyle

Daniel R Schroeder

Wenying Li

John E Leet

Grace A McClure

Xiaohua Huang

Leonard A McDonald

Robert W Myllymaki

Mahesh G Patel

Ann C Horan

Jerzy Golik

Grace A Hesler

Sandra J Hofstead

Donald R Gustavson

Ronald L Berry

Thomas T Dabrah

King S Lam

A microbial method for the preparation of an epothilone containing a terminal hydroxyalkyl group, comprising contacting at least one epothilone having a terminal alkyl group with an enzyme or microorganism capable of catalyzing the selective hydroxylation of said alkyl group to a hydroxyalkyl group, and effecting said hydroxylation.

Microbial transformation method for the preparation of an epothilone

The present invention relates to novel antitumor depsipeptides produced by Micromonospora strain 39500, ATCC 55011, and having the structural formula ##STR1## wherein R.sub.1 is 2-methylpropanoyl, and R.sub.2 is 2-methylppropanoyl, propanoyl or acetyl; or R.sub.1 is 3-methylbutanoyl, and R.sub.2 is 2-methylpropanoyl or 3-methylbutanoyl; or R.sub.1 is propanoyl, and R.sub.2 is acetyl or propanoyl.

Antitumor antibiotics

Addition of certain tryptophan analogs to the culture medium during fermentation of a rebeccamycin-producing strain of Saccharothrix aerocolonigenes results in production of new rebeccamycin analogs having advantageous antitumor properties.

Rebeccamycin analogs by tryptophan analogs feeding

A new antitumor antibiotic designated BMY-41219 is produced by fermentation of Saccharothrix aerocolonigenes ATCC 39243. The BMY-41219 antibiotic exhibits antitumor activity.

Antitumor antibiotic BMY-41219

An antitumor antibiotic designated BMY-41219 is produced by fermentation of Saccharothrix aerocolonigenes ATCC 39243. The BMY-41219 antibiotic exhibits antitumor activity.

Addition of bromine to the culture medium during fermentation of a rebeccamycin-producing strain of Saccharothrix aerocolonigenes results in production of a new rebeccamycin derivative having advantageous antineoplastic properties.

Rebeccamycin

A new antitumor antibiotic designated BMY-40800 is produced by fermentation of Streptomyces hygroscopicus ATCC 53653. The new compound inhibits the growth of tumors in experimental animals.

BMY-40800 antitumor antibiotics

Kedarcidin is a protein antitumor antibiotic produced by Streptoalloteichus sp. nov. strain L585-6, ATCC 53650. The antibiotic comprises a non-protein chromophore and a single chain polypeptide having 114 amino acid residues.

Antitumor antibiotic kedarcidin

Actinomadura melliaura nov. sp. (ATCC 39691) produces four novel compounds which we have designated AT 2433 A.sub.1, AT 2433 A.sub.2, AT 2433 B.sub.1 and AT 2433 B.sub.2. The novel compounds or pharmaceutically acceptable salts thereof exhibit antibacterial and antitumor activity.

Antibiotic, antitumor compounds and their use

A new cyclic depsipeptide antitumor antibiotic designated herein as sandramycin is produced by fermentation of a new microorganism, Nocardioides sp. strain C49,009, ATCC 39419. Sandramycin possesses antibacterial activity and inhibits the growth of tumors in experimental animals.

Process for producing antitumor antibiotic compound

Novel antitumor antibiotics designated herein as albacarcins M and V are produced by fermentation of Streptomyces albaduncas strain C-38291 (ATCC 39151). The new antibiotics possess antibacterial activity and also inhibit the growth of mammalian tumors such as P388 leukemia in mice.

Albacarcins V and M

Antitumor antibiotic compound

A new antitumor antibiotic designated herein as 4'-deschlororebeccamycin is produced by fermentation of Nocardia aerocolonigenes ATCC 39243. The new compound possesses antibacterial activity and inhibits the growth of tumors in experimental animals.

Growing community of inventors

Cheshire, CT, United States of America

James A Matson